Actively Recruiting
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Led by The University of Hong Kong · Updated on 2025-07-02
18
Participants Needed
1
Research Sites
83 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
About 70% of epithelial ovarian cancer patients are diagnosed at advanced stage. When primary optimal surgery is not possible, neoadjuvant chemotherapy will followed by interval debulking surgery is one treatment option. However, there is no consensus on the optimal timing of the surgery. CA125 is a well-known tumor marker in ovarian cancer. Its kinetic change has been proven to correlate with the patients' response to chemotherapy and chance of optimal resection. This study aims to utilize the kinetic change of CA125 to customize the timing of surgery for individual patients.
CONDITIONS
Official Title
Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must be at least 18 years old.
- Patients with Eastern Cooperative Oncology Group (ECOG) score 0-1.
- Patients able to give informed consent.
- Patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer not suitable for primary debulking surgery.
- Patients planned for neoadjuvant platinum-based chemotherapy with or without bevacizumab.
- Patients who have baseline CA125 levels at least twice the upper limit of normal.
- Patients with baseline CT abdomen and pelvis, PET-CT, or MRI scans.
- Patients agreeing to undergo interval debulking surgery with timing possibly different from usual practice.
- Patients agreeing to receive adjuvant chemotherapy with at least four cycles if needed.
You will not qualify if you...
- Patients with borderline malignancy or non-epithelial ovarian cancer like germ cell or sex cord tumors.
- Patients with metastatic disease from other origins such as Krukenberg's tumor.
- Patients eligible for primary debulking surgery.
- Patients unfit for primary surgery due to medical reasons or refusal.
- Patients who started neoadjuvant chemotherapy outside study centers except one cycle within 21 days with available baseline CA125.
- Pregnant patients.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
L
Lesley Lau, MPhil
CONTACT
I
Iris Tang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here